Evidence map›Paper›PMID 35388765›Full record

ArticleInfectious disorders drug targets2022

COVID-19 and Coinfections: A Serious Health Threat Requires Combination of Diagnosis and Therapy.

Shahid Nawaz, Maira Saleem

Abstract read
PubMed Publisher
In one paragraph

Article in Infectious disorders drug targets, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shahid NawazInstitute of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan.
Maira SaleemInstitute of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the advent of the COVID-19 pandemic in 2019, a mammoth research activity targeting the etiological features of COVID-19 has commenced. Many aspects of the disease have been studied, and various others are under consideration. The secondary microbial coinfections with COVID-19 have generated some serious concerns across the globe. This review mainly focuses on the notable secondary coinfections. The coinfection of influenza, tuberculosis, and typhoid may mimic the original COVID-19 symptoms. Physicians and clinicians must focus on the secondary coinfections which may aggravate the disease progression towards acute respiratory disorder syndrome (ARDS). Diagnostic strategies must also be redefined to determine the actual underlying secondary coinfection. There is a need for combination therapy and diagnostic approaches to minimize the risks associated with the COVID-19 pandemic effectively.

Indexed as

coinfectionCOVID-19denguehepatitisinfluenzamucormycosistyphoid

Identifiers

PMID35388765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.